| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,103 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bonstein Sara |
Chief Financial Officer |
• – – |
2015-09-30 |
4 |
A |
$10.23 |
$1,637 |
D/D |
160 |
94,430 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-09-30 |
4 |
D |
$10.23 |
$409 |
D/D |
(40) |
139,052 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-09-30 |
4 |
A |
$10.23 |
$1,954 |
D/D |
191 |
139,092 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-09-30 |
4 |
D |
$10.23 |
$266 |
D/D |
(26) |
135,866 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-09-30 |
4 |
A |
$10.23 |
$1,954 |
D/D |
191 |
135,892 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-09-30 |
4 |
D |
$10.23 |
$235 |
D/D |
(23) |
190,518 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-09-30 |
4 |
A |
$10.23 |
$1,299 |
D/D |
127 |
190,541 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-08-31 |
4 |
D |
$14.80 |
$1,613 |
D/D |
(109) |
339,227 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-08-31 |
4 |
A |
$14.80 |
$7,104 |
D/D |
480 |
339,336 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-08-31 |
4 |
D |
$14.80 |
$266 |
D/D |
(18) |
135,701 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2015-08-31 |
4 |
A |
$14.80 |
$1,954 |
D/D |
132 |
135,719 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-08-31 |
4 |
D |
$14.80 |
$237 |
D/D |
(16) |
190,414 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2015-08-31 |
4 |
A |
$14.80 |
$1,302 |
D/D |
88 |
190,430 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-08-31 |
4 |
D |
$14.80 |
$414 |
D/D |
(28) |
138,901 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2015-08-31 |
4 |
A |
$14.80 |
$1,954 |
D/D |
132 |
138,929 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-08-31 |
4 |
D |
$14.80 |
$326 |
D/D |
(22) |
94,270 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2015-08-31 |
4 |
A |
$14.80 |
$1,643 |
D/D |
111 |
94,292 |
|
- |
|
| Gross Phillip |
10% Owner |
– – • |
2015-08-24 |
4 |
B |
$12.90 |
$680,676 |
I/I |
50,000 |
5,939,366 |
1.5 |
- |
|
| Gross Phillip |
10% Owner |
– – • |
2015-08-21 |
4 |
B |
$14.21 |
$1,065,750 |
I/I |
75,000 |
5,889,366 |
1.5 |
- |
|
| Gross Phillip |
10% Owner |
– – • |
2015-08-20 |
4 |
B |
$14.17 |
$1,017,390 |
I/I |
71,182 |
5,814,366 |
1.5 |
- |
|
| Gross Phillip |
10% Owner |
– – • |
2015-08-20 |
4 |
B |
$14.28 |
$1,482,521 |
I/I |
103,818 |
5,743,184 |
1.5 |
- |
|
| Ridge Thomas J |
Director |
– • – |
2015-08-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,876 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-07-31 |
4 |
S |
$15.44 |
$130,453 |
D/D |
(8,449) |
338,856 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-07-31 |
4 |
D |
$16.66 |
$5,415 |
D/D |
(325) |
347,305 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2015-07-31 |
4 |
A |
$16.66 |
$10,662 |
D/D |
640 |
347,630 |
|
- |
|
586 Records found
|
|
Page 11 of 24 |
|
|
